期刊文献+

心肾功能对万古霉素的清除率影响分析 被引量:10

Analysis the influence of cardiac and renal function on vancomycin clearance rate
原文传递
导出
摘要 目的:评估心脏病患者的心脏功能及肾功能对万古霉素清除率的影响。方法:对303例患者在使用了万古霉素注射1 h后以及下一次用药前的血清浓度进行检测,同时检测患者左心室射血分数(LVEF)。根据2次检测结果计算万古霉素的药动学参数。结果:LVEF<50%(69例)的患者以及50%≤LVEF<75%的患者(108例),其万古霉素的清除率显著低于LVEF≥75%(126例)的患者[万古霉素清除率分别为(2.39±0.94)和(2.78±0.98)L·h-1 vs(3.51±1.05)L·h-1 P<0.001或P<0.01]。万古霉素的清除率不仅与LVEF<50%(r=0.827)和50%≤LVEF<75%(r=0.774)患者的肌酐清除率的估计值高度相关,同时与肌酐清除率(Ccr)<60 ml·min-1患者的左心室射血分数有关(r=0.645)。Logisitic回归分析提示Ccr、LVEF和体质量是万古霉素清除率的重要的独立变量(r2=0.650)。结论:万古霉素清除率随着LVEF和Ccr的降低而降低。提示万古霉素清除率除受到患者肾功能影响外还受到患者心脏功能的影响,因此在临床使用中需要参考患者的Ccr和LVEF数值来调整万古霉素的用量。 OBJECTIVE To evaluate the influences of cardiac and renal functions on vancomycin(aglycopeptide antibiotic)clearance rate in patients with cardiac diseases.METHODS The study selected 303 patients with left ventricle ejection fraction(LVEF)detected.Vancomycin serum concentration was determined1 hour before and after injection.Pharmacokinetic parameters were estimated based on the above results.RESULTS In patients with LVEF50%(69 cases)and 50%≤LVEF75%(108 cases),clearance rate of vancomycin was lower than that in patients with LVEF≥75%(126 cases)(2.39±0.94 and 2.78±0.98 L·h^-1 vs.3.51±1.05 L·h^-1;P〈0.001 or P〈0.01).Vancomycin clearance was not only affected by creatinine clearance rate in patients with LVEF〈50%(r=0.827)and 50%≤LVEF75%(r=0.774),but also LVEF in patients with a creatinine clearance rate(Ccr)〈60 ml·min^-1.Logistic regression analysis revealed that Ccr,LVEF and body weight were important independent variables(r^2=0.650)for vancomycin clearance.CONCLUSION Vancomycin clearance decreases as LVEF and Ccr decrease.These results suggest that vancomycin clearance rate is not only influenced by renal function,but also by cardiac function.Therefore,we need to adjust vancomycin dose by considering Ccr and LVEF values.
出处 《中国医院药学杂志》 CAS CSCD 北大核心 2015年第9期825-829,共5页 Chinese Journal of Hospital Pharmacy
基金 河北省卫生厅基金项目(编号:20130416)
关键词 万古霉素 射血分数 肌酐清除率 vancomycinl ejection fractionl creatinine clearance rate
  • 相关文献

参考文献4

二级参考文献26

  • 1Rybak M,Lomaestro B.Rotschafer J C,et al.Therapeutic monitoring of vancomycin in adult patients:a consensus review of the American Society of Health-System Pharmacists,the Infectious Diseases Society of America,and the Society of Infectious Diseases Pharmacists[J].Am J Health Syst Pharm,2009,66:82-98.(http://www.ashp.org/DocLibrary/BestPractices/BPVancoAJHP.aspx). 被引量:1
  • 2Canadian Task Force on the Periodic Health Examination.The periodic health examination[J].Can Med Assoe J,1979,121:1193-1254. 被引量:1
  • 3Rybak M, Lomaestro B, Rotschafer JC, et al. Thera- peutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health- System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Phar- macists[J]. Am J Health Syst Pharm, 2009, 66(1): 82-98. 被引量:1
  • 4Lo YL, van Hasseh JG, Heng SC, et al. Population pharmaeokinetics of vancomycin in premature Malaysian neonates: identification of predictors for dosing determi- nation [J]. Antimicrob Agents Chemother, 2010, 54(6): 2626-32. 被引量:1
  • 5Staatz CE, Byrne C, Thomson AH. Population pharma- eokinetie modelling of gentamicin and vancomycin in patients with unstable renal funetion following cardiotho- racie surgery[J]. Br J Clin Pharmacol, 2006, 61(2): 164-76. 被引量:1
  • 6Buelga DS, del Mar Fernandez de Gatta M, Henera EV, et al. Population pharmacokinetic analysis of van- comycin in patients with hematological malignancies[J]. Antimicrob Agents Chemother, 2005, 49(12): 4934-41. 被引量:1
  • 7Wrishko RE, Levine M, Khoo D, et al. Vancomycin pharmacokinetics and Bayesian estimation in pediatric patients[J]. Ther Drug Moult, 2000, 22(5): 522-31. 被引量:1
  • 8Sanchez JL, Dominguez AR, Lane JR, et al. Popula- tion pharmacokinetics of vancomycin in adult and geriatric patients: comparison of eleven approaches[J]. Int J Clin Pharmacol Ther, 2010, 48(8): 525-33. 被引量:1
  • 9Zhang J, Zhang Y, Shi Y, et al. Population pharma- cokinetic and pharmacodynamic modeling of norvan- comycin[J]. Eur J Clin Microbiol Infect Dis, 2008, 27 (4): 275-84. 被引量:1
  • 10Mulla H, Pooboni S. Population pharmacokinetics of vancomycin in patients receiving extracorporeal mem- brane oxygenation [J]. Br J Clin Pharmacol, 2005, 60 (3): 265-75. 被引量:1

共引文献633

同被引文献58

引证文献10

二级引证文献52

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部